According to a recent LinkedIn post from Neuromod Devices Ltd, the Atlanta VA Health Care System has begun using the company’s Lenire tinnitus treatment technology, with the first use recorded on April 2, 2026. The post notes that an Army Veteran, identified as Profit Lucy, is among the first patients at the facility to receive the therapy and is quoted describing it as an advancement that may improve quality of life.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that tinnitus affects 3.2 million U.S. Veterans and is described as the number one service-connected disability in the latest Annual Benefits Report. This early clinical adoption within a major VA system suggests growing institutional validation for Lenire, which could support future demand in the U.S. veterans’ healthcare channel and potentially strengthen Neuromod’s positioning in the broader tinnitus treatment market.